Increased plasma GLP-1 levels due to DGAT1 inhibition in humans and animals models leads to delayed gastric emptying, which might lead to vomiting and diarrhea in humans [8,24].Thus, understanding and exploring the chylomicron neutral lipid balance could help in generating better tolerable inhibitors targeting the gut metabolism to treat hyperlipidemia and obesity. The gene discussed is DGAT1; the disease is obesity disorder.